GLP-1 Patient Support Market Set to Hit $2.85 Billion by 2036, Driven by Onboarding Demand
The market for GLP-1 patient support services is growing fast. Fact.MR now pegs it at $545 million in 2026. By 2036, it expects that number to reach $2.85 billion. That works out to an 18 percent annual growth rate. In dollar terms, it means roughly $2.31 billion in new demand over the next decade.
Why the surge? GLP-1 drugs like semaglutide and tirzepatide have exploded in popularity. Doctors prescribe them widely for type 2 diabetes and obesity. But getting patients started on these medications, and keeping them on track, turns out to be harder than it looks.
That’s where onboarding comes in. Injection training and initial setup make up the single largest slice of the support market, at nearly 38 percent. And there’s a good reason for that. Patients who fumble through their first few weeks of self-injecting often give up entirely.
GLP-1 drugs also require careful dose titration. Ramping up too quickly can trigger nausea and other gastrointestinal side effects. So those early weeks matter enormously. Get them right, and patient adherence tends to hold. Get them wrong, and it falls apart fast.
Digital tools have become the preferred way to deliver this support. Digital-first platforms now account for about 35 percent of the market. They make sense from a scaling standpoint. Reaching millions of patients through in-person counseling simply isn’t realistic or affordable, especially given the steep cost of these medications to begin with.
Pharmaceutical manufacturers are driving much of this growth themselves. They sponsor more than half of all support programs, and they’re also the largest end users. That concentration brings real regulatory scrutiny, though. When drugmakers fund patient support directly, the line between genuine assistance and marketing can get blurry.
The FDA keeps a close eye on this. Promotional communications tied to prescription drugs face strict oversight. Copay assistance programs, in particular, can run into trouble under federal anti-kickback rules if they’re seen as influencing prescribing decisions. As a result, companies need to keep clinical education, like injection training, clearly separate from anything promotional.
Geographically, the United States leads the pack. American growth is projected at 17.5 percent annually, ahead of Germany and France. That’s largely because so much GLP-1 prescribing already happens here, alongside a heavy concentration of manufacturer-run digital hubs.
Still, access remains a real obstacle. Insurance prior authorization requirements slow things down. Medicaid coverage for anti-obesity medications varies wildly from state to state, which only adds friction for patients trying to start therapy.
Fragmentation is another challenge facing the industry. When onboarding, financial assistance, and ongoing support operate as separate, disconnected pieces, patients notice. The experience feels choppy, and dropout risk climbs. Proving that a support program actually improves adherence is tricky too, since so many other factors affect whether someone stays on their medication.
Some companies are already working to fix this. Firms like EVERSANA, CareMetx, and CoverMyMeds have started building integrated platforms that combine onboarding, financial help, and long-term outreach into a single experience.
Ultimately, the data points to something worth noting: it’s not just the medication that determines success. How well patients get onboarded onto drugs like Ozempic, Wegovy, or Mounjaro may matter just as much. As prescribing volume keeps climbing, expect regulators to pay even closer attention to how manufacturers run these support programs.
